Frequency Therapeutics participates in a conference call with JPMorgan » 09:2310/1910/19/20
SMid Cap Biotech Analyst…
SMid Cap Biotech Analyst Rama holds a conference call with CEO Lucchino on October 19 at 11 am hosted by JPMorgan.
Frequency Therapeutics management to meet virtually with Oppenheimer » 04:5510/1910/19/20
Virtual Meetings to be…
Story temporarily locked.
Frequency Therapeutics management to meet virtually with Oppenheimer » 10:4010/1610/16/20
Virtual Meetings to be…
Virtual Meetings to be held October 19-21 hosted by Oppenheimer.
|Over a week ago|
Frequency Therapeutics completes patient enrollment of FX-322 » 07:3209/2209/22/20
Frequency Therapeutics announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss, or SNHL. The company anticipates obtaining full results for the study, in which 95 patients were enrolled, in Q2 of 2021.
|Over a month ago|
Frequency presents results from longer-term durability study of FX-322 » 15:2409/1309/13/20
Frequency Therapeutics presented clinical results from a longer-term durability study of FX-322, showing that some patients with chronic sensorineural hearing loss had significant improvement in key measures of hearing that were sustained for up to 21 months. These new data build upon Phase 1/2 study results previously detailed at the 2019 AAO-HNS conference that showed, for the first time, statistically significant improvements in word recognition scores in patients with chronic moderate to moderately severe SNHL. These patients had received a single intratympanic dose of FX-322 in a double-blind, placebo-controlled study, and had been evaluated for 90 days. Subsequent testing of a subset of these patients between 13 and 21 months after initial dosing, showed sustained improvements in measures of speech intelligibility (clarity), and in some patients, increased audibility threshold values at a higher frequency. Four of the patients that were observed to have statistically significant WR scores during the Phase 1/2 study had maintained those improvements in the follow up assessment. Three of these patients remained at statistically significant levels, maintaining an average increase of 87% in WR scores from their original baseline levels. The other patient maintained a 71% increase from their initial baseline, though that sustained improvement fell outside the range of statistical significance. An additional patient who did not achieve statistically significant change in WR during the Phase 1/2 study was also retested, and it was observed that their WR score had returned to baseline. Moreover, three of the patients that maintained statistically significant WR scores also showed 10-15dB improvements at 8000Hz compared to their original threshold values at this frequency. The safety profile observed in the FX-322 Phase 1/2 study was favorable and no additional safety findings were observed in the follow-up period. Together, these longer-term clinical data demonstrate the potential for FX-322 to have a durable positive impact both on measures of hearing clarity and volume.
Frequency Therapeutics files to sell 2.35M shares of common stock for holders 16:1808/2808/28/20
Frequency Therapeutics reports Q2 EPS (19c), consensus (18c) » 07:3608/1208/12/20
Reports Q2 revenue…
Reports Q2 revenue $8.52M, consensus $6.14M. "We are pleased with the steady progress in our Phase 2a study, despite the challenges of the pandemic, and we anticipate completing enrollment early in the fourth quarter of 2020 and sharing data from the study in the second quarter of 2021," said Frequency Therapeutics CEO David Lucchino. "In the last quarter, we generated compelling cochlear drug delivery data for FX-322, as well as important durability data suggesting that some patients who were given a single injection of FX-322 in our original Phase 1/2 study maintained statistically significant improvements in word recognition between 12 and 21 months following administration. We believe that these clinical advances are important building blocks as we work to further our understanding of FX-322 drug activity and the patient populations we hope to treat."
|Over a quarter ago|
Fly Intel: After-Hours Movers » 18:5807/1307/13/20
INMB, VNDA, FREQ, EW, BA, OSMT, ALT
Check out this evening's…
Frequency Therapeutics initiated with an Outperform at Oppenheimer » 16:1007/1307/13/20
Oppenheimer analyst Jay…
Oppenheimer analyst Jay Olson initiated coverage of Frequency Therapeutics with an Outperform rating and $36 price target. The analyst said that, given the substantial market opportunity and limited treatment options available, he believes Frequency's FX-322 holds the promise to "revolutionize" the treatment of hearing loss.
Healthcare Financial Management Association to hold a virtual conference » 08:5606/2406/24/20
MTBC, NVZMY, NVS, NVAX, MRK, LOGI, REGN, RDY, FREQ, RCKT, TRVI, CSU, NVO
HFMA 2020 Digital Annual…
HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link